Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2000 3
2001 2
2002 1
2003 1
2004 1
2005 2
2007 2
2009 2
2010 4
2011 3
2012 5
2013 2
2014 4
2015 3
2016 5
2017 7
2018 5
2019 6
2020 10
2021 10
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Caimi PF, et al. Among authors: ardeshna km. Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989558 Clinical Trial.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS. Hamadani M, et al. Among authors: ardeshna km. Blood. 2021 May 13;137(19):2634-2645. doi: 10.1182/blood.2020007512. Blood. 2021. PMID: 33211842 Free PMC article. Clinical Trial.
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MDC, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. van Imhoff GW, et al. Among authors: ardeshna km. J Clin Oncol. 2017 Feb 10;35(5):544-551. doi: 10.1200/JCO.2016.69.0198. Epub 2016 Dec 28. J Clin Oncol. 2017. PMID: 28029326 Clinical Trial.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: ardeshna km. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Ardeshna KM, et al. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4. Lancet Oncol. 2014. PMID: 24602760 Clinical Trial.
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Alderuccio JP, et al. Among authors: ardeshna km. Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782. Blood Adv. 2022. PMID: 35790100 Free PMC article. No abstract available.
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Hamadani M, et al. Among authors: ardeshna km. Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636. Blood Adv. 2024. PMID: 37871303 Free PMC article. No abstract available.
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, Verhoef G, Cunningham D, de Vos S, Kassam S, Fayad L, Radford J, Bailly S, Offner F, Morgan D, Munoz J, Ping J, Szafer-Glusman E, Eckert K, Neuenburg JK, Goy A. Ramchandren R, et al. Among authors: ardeshna km. EClinicalMedicine. 2022 Dec 26;56:101779. doi: 10.1016/j.eclinm.2022.101779. eCollection 2023 Feb. EClinicalMedicine. 2022. PMID: 36618900 Free PMC article.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Among authors: ardeshna km. Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283459. Online ahead of print. Haematologica. 2023. PMID: 37646659 Free article.
73 results